METASTATIC MALIGNANT SOLID NEOPLASM

This trial tests a vaccine called LabVax 3(22)-23, designed to help the immune system recognize and attack a protein called labyrinthin found on adenocarcinoma tumor cells. The study includes adults with advanced or metastatic adenocarcinoma and will evaluate the vaccine alone or…

This study tests whether adding the targeted drug ipatasertib to standard chemotherapy (paclitaxel) can shrink or slow the growth of advanced solid tumors that have specific changes in the PTEN or AKT genes. About 33 adults whose cancer has spread or cannot be removed by surgery …

This phase 3 trial is testing whether adding radiation therapy to standard care can prevent bone complications like fractures or spinal cord compression in cancer patients with high-risk bone metastases that aren't causing symptoms yet. About 280 patients with multiple metastatic…

This early-phase trial tests a combination of three drugs—copanlisib, olaparib, and durvalumab—in people with advanced solid tumors that have spread or can't be removed by surgery. The goal is to find the safest dose and see if the drugs work together to shrink tumors. Only patie…

This early-stage trial tests the safety and best dose of two oral drugs, ZEN003694 and binimetinib, taken together. It is for people with advanced solid tumors that have RAS pathway changes or triple-negative breast cancer that has spread or cannot be removed. The goal is to find…

This early-phase trial tests the safety and best dose of two drugs—neratinib and trastuzumab deruxtecan—given together to people with advanced solid tumors that have HER2 gene changes. The goal is to see if the combination can shrink tumors that have spread or can't be removed by…

This early-phase study tests the safety and best dose of a drug called veliparib when given with two chemotherapy drugs (carboplatin and paclitaxel) in people with advanced solid tumors that have spread or can't be removed. It includes patients who also have liver or kidney probl…

This phase II trial tests a drug called telaglenastat (CB-839) in people with advanced solid tumors that have specific genetic changes, including NF1 mutations and malignant peripheral nerve sheath tumors. The drug works by blocking an enzyme that cancer cells need to grow. Resea…

This study tests whether adding the targeted drug copanlisib to two immunotherapy drugs (nivolumab and ipilimumab) can better control advanced solid tumors that have changes in the PIK3CA or PTEN genes. About 54 adults with cancers that have spread or cannot be removed will recei…

This early-phase trial tested two drugs, adavosertib and olaparib, given one after the other in 13 people with advanced solid tumors that had specific DNA repair mutations. The goal was to find the best dose and see if this sequence causes fewer side effects than taking both drug…

This early-phase trial tests a combination of copanlisib (a targeted drug) with nivolumab (an immunotherapy) in people with advanced solid tumors or lymphoma. Some participants will also receive a third drug, ipilimumab. The main goals are to find the safest dose and to monitor s…

This phase 2 trial tests whether combining nilotinib (a targeted drug) with paclitaxel (a chemotherapy drug) can help patients whose solid tumors have grown despite prior taxane treatment. About 40 adults with advanced or resistant cancers will receive the combination. The study …

This early-phase trial is testing a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (a drug that may block cancer cell repair)—in people with advanced solid tumors that have a HER2 mutation. The study has two parts: first, finding the sa…

This early-phase study tests the safety of the immunotherapy drug atezolizumab given after a patient's own immune cells have been modified and infused back (adoptive cell transfer). It includes 40 adults with advanced blood or solid cancers that no longer respond to standard trea…

This study tests a drug called adavosertib in adults with advanced solid tumors that have a missing or broken SETD2 gene. The drug works by blocking enzymes that cancer cells need to grow. Researchers want to see if it can shrink tumors or keep them stable for at least 6 months.

This study tests a combination of two drugs, avelumab and M6620, in people with advanced solid tumors that have spread or can't be removed by surgery. The tumors must have a specific DNA repair defect. The goal is to find the safest dose and see if the combination can help contro…

This study tests a combination of two drugs (peposertib and avelumab) plus a special type of radiation (hypofractionated) in people with advanced solid tumors or liver/bile duct cancers that have spread. The goal is to find the safest dose and see if the combination can shrink tu…

This early-phase trial tests a new drug called BAY 1895344 combined with standard chemotherapy (irinotecan or topotecan) in people with advanced solid tumors, especially small cell lung cancer, poorly differentiated neuroendocrine cancer, and pancreatic cancer. The goal is to fin…

This study tests a combination of two drugs, trametinib and navitoclax, in people with advanced solid tumors that have specific mutations in the KRAS or NRAS genes. The goal is to find the safest dose and see if the drugs can shrink tumors or slow their growth. About 96 participa…

This early-phase trial tests the safety of combining two cancer drugs, nivolumab and cabozantinib, in people with HIV who have advanced solid tumors. Only 8 participants were enrolled. The goal is to see if the combination is safe and can shrink or stabilize tumors.

This early-stage trial tests a new drug (DS3201) combined with an immunotherapy (ipilimumab) in people whose prostate, bladder, or kidney cancer has spread. The main goals are to find the safest dose and see what side effects occur. About 65 participants will receive both drugs t…

This early-phase trial tests the combination of two oral drugs, ceritinib and everolimus, in people with advanced solid tumors or a specific type of lung cancer (ALK-positive NSCLC) that has stopped responding to standard treatments. The main goal is to find a safe dose and look …

This early-phase trial is testing a combination of two immunotherapy drugs—pembrolizumab and recombinant interleukin-12—in 36 adults with advanced solid tumors that have not responded to standard treatments. The goal is to find the safest dose and see if the combination can help …

This early-phase trial tests a new drug called M6620 (berzosertib) combined with the chemotherapy irinotecan in people with advanced solid tumors that have spread or can't be removed. The goal is to find the safest dose and see if the combination can slow tumor growth. About 66 p…

This phase II trial tests whether adding panitumumab to sotorasib works better than sotorasib alone for advanced solid tumors that have a KRAS G12C mutation. About 105 adults with these cancers will be randomly assigned to one of two groups. The main goal is to see if the combina…

This phase II trial tests whether radiation therapy can help control cancer that has spread or grown after immunotherapy. About 230 patients with metastatic or lymphoid cancers will receive targeted radiation to see if it stabilizes the disease or shrinks tumors. The study also m…

This early-phase trial tests a combination of two drugs—pembrolizumab (an immunotherapy that helps the immune system fight cancer) and ziv-aflibercept (which cuts off blood supply to tumors)—in people with advanced solid tumors like melanoma, colorectal, ovarian, and kidney cance…

This early-phase trial tests a new drug called ZEN003694, which blocks certain enzymes that help cancer grow, combined with two immunotherapy drugs (nivolumab and ipilimumab) that boost the immune system to attack cancer. The study includes 66 adults with advanced solid tumors, i…

This study tests the safety and effectiveness of combining the immunotherapy drug avelumab with other treatments (utomilumab, ivuxolimab, or radiation) in 173 people with advanced cancers that have not responded to standard therapies. The goal is to find tolerable doses and see i…

This study tested a combination of two drugs, veliparib and topotecan, in 88 patients with solid tumors or ovarian cancer that returned after initial treatment. The goal was to find the safest dose and see how well the drugs shrink tumors. While the treatment aims to control the …

This study tests a drug called ceralasertib, alone or with olaparib or durvalumab, in people with advanced solid tumors like kidney, bladder, pancreatic, and endometrial cancers. The goal is to see if these combinations can shrink tumors by blocking enzymes that help cancer grow.…

This study tests whether the immunotherapy drug nivolumab can help control cancer in 16 people with advanced solid tumors that have spread or can't be removed by surgery. Participants must have a specific genetic change (ARID1A mutation) and a protein marker (CXCL13) in their tum…

This phase 2 trial tests whether genetic testing can help doctors pick the right targeted drug for people whose solid tumors have spread to the brain. About 50 participants with specific gene mutations (like NTRK, ROS1, CDK, PI3K, or KRAS G12C) will receive one of four drugs: abe…

This phase 2 trial tests whether pembrolizumab (Keytruda) can shrink or control advanced solid tumors that have certain gene mutations (BRCA1, BRCA2, POLE, POLD1). The study enrolled 21 adults with cancers that have spread or come back. Researchers measure how many patients see t…

This early-phase trial tests two drugs together—sonidegib and pembrolizumab—in 36 adults with advanced solid tumors that have spread. Sonidegib blocks a growth signal in cancer cells, while pembrolizumab helps the immune system attack the tumor. The main goals are to find the saf…

This early-phase trial is testing a drug called DS-8201a in 62 adults with advanced HER2-positive solid tumors that have not responded to standard treatments. The drug works by attaching to the HER2 protein on cancer cells and damaging their DNA, which may kill the cells. Researc…

This study tested a drug called pembrolizumab in 157 people with rare cancers that had spread or couldn't be removed. The drug works by helping the body's immune system attack the cancer. The main goal was to see how many patients were alive and their cancer hadn't grown after 27…

This early-stage trial tests the safety and best dose of the drug neratinib when combined with one of three other drugs (everolimus, palbociclib, or trametinib) in people with advanced solid tumors that have certain gene mutations or amplifications. The study enrolls 93 participa…

This early-phase study tests a combination of two drugs, niraparib and dostarlimab, in 18 adults with BRCA-mutated breast, pancreas, or ovary cancer that has spread or cannot be surgically removed. Niraparib blocks a DNA repair protein in cancer cells, while dostarlimab helps the…

This early-stage trial aimed to test the safety of a new treatment called STIL101 for people with advanced pancreatic, colorectal, kidney, cervical cancer, or melanoma that has spread or cannot be removed. STIL101 is made from a patient's own immune cells taken from their tumor, …

This was a phase I trial testing a new drug called CB-5339 in people with advanced solid tumors or lymphomas. The drug was designed to block certain enzymes that cancer cells need to grow. However, the study was withdrawn before enrolling any participants, so no results or safety…

This study tests whether injecting bone cement into the spine can prevent fractures after high-dose radiation treatment for cancer that has spread to the backbone. About 87 patients with solid tumors and spinal metastases will receive either standard radiation alone or radiation …

This study tests whether a drug called anamorelin, combined with physical activity and nutritional counseling, can reduce severe fatigue in people with advanced solid tumors that have spread or returned. About 129 participants with incurable cancers and high fatigue levels will r…

This study tests whether an open labeled placebo—a pill with no active medicine that patients know is a placebo—can reduce fatigue in people with advanced cancer. About 100 participants will either receive the placebo or be placed on a waitlist. The goal is to see if simply takin…

This study looks at two different methods—a Virtual Learning Collaborative or Technical Assistance—for delivering a palliative care program called ENABLE to people with advanced cancer and their caregivers. Palliative care focuses on relieving symptoms, reducing stress, and impro…

This study tests whether early visits with a brain health specialist can help people with cancer that has spread to the brain maintain their quality of life after radiation therapy. About 110 adults with solid tumors and brain metastases will receive neuropsychological care along…

This study tests whether adding the steroid dexamethasone to a physical activity program helps reduce severe fatigue in people with advanced cancer. About 99 participants will take the drug or a placebo while doing strength and walking exercises. The goal is to see if the combina…

This study follows nearly 1,900 cancer patients who tested positive for COVID-19. Researchers collect blood samples, medical records, and images to see how the virus impacts their cancer treatment and overall health. The goal is to learn which factors make COVID-19 more severe in…

This study looks at whether a financial navigation program can help cancer patients and their partners manage the high costs of treatment. About 331 people with advanced cancer will get either the program or usual care. The goal is to see if this support reduces financial hardshi…

This study uses a brain wave test (EEG) to check if cancer patients who seem unresponsive in their last days can still hear or feel. Researchers will measure brain activity when sounds or words are played. The goal is to help families and doctors understand what patients may expe…

This study tests whether watching a short video can improve understanding of tumor genomic testing in 243 adults with metastatic cancer. Participants watch the video and then answer questions to measure their knowledge. The goal is to see if this simple tool helps patients better…

This study looks at how often cancer patients experience cachexia (unintentional weight loss and appetite loss) and how this affects both patients and their primary caregivers emotionally. About 192 patients and their caregivers will fill out questionnaires during supportive care…

This study looks at whether a special team of doctors and scientists (a genomic tumor board) can help more patients with advanced solid tumors get treatments that match their cancer's genetic makeup. About 1,284 patients will take part. The goal is to see if this team approach le…